Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

Autor: Masayoshi Yokoyama, Kenichi Nishimura, Noriyoshi Miura, Yuki Miyauchi, Nozomu Tanji, Akitomi Shirato, Seiji Asai, Yutaka Yanagihara, Terutaka Noda, Tadahiko Kikugawa
Rok vydání: 2015
Předmět:
Male
0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Docetaxel
urologic and male genital diseases
Gastroenterology
Dexamethasone
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Drug Discovery
medicine
Humans
Pharmacology (medical)
Survival rate
Aged
Neoplasm Staging
Retrospective Studies
Aged
80 and over
Pharmacology
Chemotherapy
Dose-Response Relationship
Drug
business.industry
Retrospective cohort study
General Medicine
Middle Aged
Prognosis
medicine.disease
Survival Rate
Prostatic Neoplasms
Castration-Resistant
030104 developmental biology
Infectious Diseases
030220 oncology & carcinogenesis
Toxicity
Feasibility Studies
Taxoids
business
Febrile neutropenia
Follow-Up Studies
medicine.drug
Zdroj: Chemotherapy. 61:23-31
ISSN: 1421-9794
0009-3157
Popis: Aim: Docetaxel-based chemotherapy against castration-resistant prostate cancer (CRPC) has recently been shown to be effective and tolerable. The objective of this study was to retrospectively evaluate the efficacy and toxicity of low-dose docetaxel in combination with dexamethasone. Methods: Thirty-seven CRPC patients were administered a treatment regimen consisting of 50 mg/m2 docetaxel once every 3-4 weeks and 1 mg dexamethasone daily at our institution, between November 2004 and April 2014. Results: Twenty-four patients (65%) had a decrease in serum prostate-specific antigen (PSA) >50%. The median overall survival (OS) and PSA progression-free survival were 26.2 and 10.0 months, respectively. Ten of 12 patients (83%) taking analgesic agents reduced their intake because of decreased pain levels. Grade 3 febrile neutropenia occurred in 2 patients (5%). Nonhematological toxicities were less frequent but sometimes severe. Treatment-related death occurred in 2 octogenarian patients, 1 due to gastric bleeding and the other due to infective endocarditis. Conclusion: Low-dose docetaxel in combination with dexamethasone is feasible in Japanese CRPC patients. Hematological toxicity is less than that seen with standard docetaxel therapy, but it is necessary to monitor patients for severe nonhematological toxicities, particularly very elderly patients.
Databáze: OpenAIRE
Externí odkaz: